184 related articles for article (PubMed ID: 196739)
1. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
[TBL] [Abstract][Full Text] [Related]
2. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.
Batliwalla FM; Bateman BA; Serrano D; Murray D; Macphail S; Maino VC; Ansel JC; Gregersen PK; Armstrong CA
Mol Med; 1998 Dec; 4(12):783-94. PubMed ID: 9990864
[TBL] [Abstract][Full Text] [Related]
3. Viral oncolysate in the management of malignant melanoma. II. Clinical studies.
Murray DR; Cassel WA; Torbin AH; Olkowski ZL; Moore ME
Cancer; 1977 Aug; 40(2):680-6. PubMed ID: 196740
[TBL] [Abstract][Full Text] [Related]
4. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
Kokoschka EM
Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
[No Abstract] [Full Text] [Related]
5. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
6. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for melanoma.
Vaisrub S
JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
[No Abstract] [Full Text] [Related]
8. Immunology of human malignant melanoma.
Lewis MG
Ser Haematol; 1972; 5(5):44-65. PubMed ID: 4598040
[No Abstract] [Full Text] [Related]
9. [Value of ultrastructural morphology in the preparation of oncolysates of human malignant melanoma].
Noël P; Faucon M; Leftheriotis E; Fontanière B; Bailly C; Carcagne C; Groleas M; Rezvoy M
Ann Anat Pathol (Paris); 1979; 24(2):125-35. PubMed ID: 525843
[TBL] [Abstract][Full Text] [Related]
10. Active specific adjuvant immunotherapy with vaccinia melanoma oncolysate.
Scoggin SD; Sivanandham M; Sperry RG; Wallack MK
Ann Plast Surg; 1992 Jan; 28(1):108-9. PubMed ID: 1642396
[TBL] [Abstract][Full Text] [Related]
11. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Vanwijck R; Bouillenne C; Malek-Mansour S
Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
[No Abstract] [Full Text] [Related]
12. [Immunotherapy].
Lejeune FJ; Bernheim JL; Vanwijck R
Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
[No Abstract] [Full Text] [Related]
13. [Immunological aspects in malignant melanoma].
Macher E
Arch Dermatol Forsch; 1972; 244():234-9. PubMed ID: 4675197
[No Abstract] [Full Text] [Related]
14. Immunotherapy for human malignant melanoma.
Kopf AW
South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
[TBL] [Abstract][Full Text] [Related]
15. [The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
Glinkina LS; Bruvere RZh
Vopr Onkol; 1992; 38(6):659-66. PubMed ID: 1300766
[TBL] [Abstract][Full Text] [Related]
16. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
17. Intralesional BCG in the treatment of metastatic malignant melanoma.
Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
[TBL] [Abstract][Full Text] [Related]
18. A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate.
Cassel WA; Murray DR; Phillips HS
Cancer; 1983 Sep; 52(5):856-60. PubMed ID: 6871827
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous regression of malignant melanoma. Pathologic and immunologic study in a ten year survivor.
Maurer H; McIntyre OR; Rueckert F
Am J Surg; 1974 Apr; 127(4):397-403. PubMed ID: 4274502
[No Abstract] [Full Text] [Related]
20. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
